IO Combos Yield OS Advantage Vs Chemo Alone in Stage IV PD-L1–Negative NSCLC

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

Related Keywords

Pennsylvania ,United States ,Fox Chase ,University Of Pennsylvania ,New York ,Philadelphia ,Edmundm Dunn ,Hossein Borghaei ,Merck Celgene ,Amgen ,Pfizer ,Novartis ,Genentech ,Department Of Hematology Oncology ,Cart Program ,Thoracic Oncology At Fox Chase Cancer Center ,Division Of Thoracic Medical Oncology ,Safety Monitoring Board For University Of Pennsylvania ,Astrazeneca ,Boehringer Ingelheim ,Annual New York Lung Cancers Symposium ,Thoracic Medical Oncology ,Immune Monitoring Facility ,Thoracic Oncology ,Fox Chase Cancer Center ,World Data ,Advisory Board ,Scientific Advisory Board ,Stock Options ,Safety Monitoring Board ,